NEW YORK – GenEdit on Tuesday said it has inked a multiyear collaboration and license agreement with Roche's Genentech to develop novel nanoparticles for use in autoimmune disease therapies.
South San Francisco, California-based GenEdit, a firm that develops in vivo genetic medicines, and Genentech, also based in South San Francisco, will use GenEdit's NanoGalaxy platform to discover and develop hydrophilic nanoparticles for therapy delivery that Genentech can use as it develops nucleic acid-based medicines for autoimmune diseases.
Genentech will be responsible for preclinical, clinical, and regulatory development and potential commercialization of products that result from the collaboration.
"Our collaboration with GenEdit will use their polymer nanoparticle library and platform with the potential to reshape treatment paradigms to help people with devastating and difficult-to-treat autoimmune disease," James Sabry, global head of Roche Pharma Partnering, said in a statement.
Under the terms of the agreement, Genentech will pay GenEdit $15 million upfront. GenEdit is also eligible to receive up to $629 million in near-term, preclinical and clinical development, commercial, and net sales milestone payments, as well as tiered royalties based on global net sales from potential resulting products.